arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Viatris Inc

VTRS
$16.41 ▲ +0.14 (+0.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Viatris Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield 2.93%
Revenue Growth -3.0%
Op. Margin -18.6%
ROIC -20.5%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.30B
↓ -3.0%
Net Income Profit after all expenses
$-3.51B
↓ -454.2%
Operating Margin Operating profit as % of sales
-18.6%
↓ -27277.5% 11th
FCF / Share Free cash flow per share
$2.10
↓ -0.8%
Long-Term Debt Long-term obligations
$12.48B
↓ -11.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
30
Financial Health
35
Cash Quality
13

Dividend History

Dividend / share · sourced from SEC filings
$0.48 Latest / share
+0.0% YoY
+34.3% 6-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters